Blood Disorders & Hematology Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5

This Phase 3 trial is testing a new drug called surovatamig alongside the standard chemotherapy treatment known as R-CHOP for adults with untreated large B-cell lymphoma. The goal is to see if adding surovatamig can improve treatment results for this aggressive blood cancer, potentially helping patients live longer or with fewer symptoms. Although the study is not yet recruiting, it plans to include 1200 participants aged 18 to under 80, offering hope for improved therapy in this common lymphoma type.

A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma

This Phase 2 study explores the use of pembrolizumab, an immunotherapy drug, as the first treatment for patients with Hodgkin lymphoma who cannot have standard chemotherapy. This could provide a new option for patients who need gentler treatments or have health issues that prevent chemotherapy. Conducted in Australia and New Zealand with 27 participants, the trial’s results are still pending and could shape future care for these patients.

Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study

This study is testing a combination of polatuzumab vedotin, rituximab, and lower doses of chemotherapy drugs in elderly patients with diffuse large B-cell lymphoma. It aims to find a safer yet effective treatment for older or frail patients who may not tolerate full-dose chemotherapy well. Recruiting now in China, this research could lead to gentler treatment plans that still control the disease effectively.

Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy

This trial is testing gene therapy in children with transfusion-dependent beta-thalassemia, a rare blood disorder requiring lifelong blood transfusions. By potentially reducing the need for transfusions, the therapy aims to improve children's growth, development, and quality of life. Recruiting in China with a goal of 100 children, this study could offer a significant advance for young patients managing this chronic condition.

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

This Phase 2 trial is evaluating blinatumomab, an immunotherapy, in children whose B precursor acute lymphoblastic leukemia has returned or not responded to previous treatments. The study hopes to improve remission rates and provide new options for children facing limited alternatives. Conducted in China with 18 participants, this research may expand treatment choices for this challenging form of childhood leukemia.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.